Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Acute kidney injury

Cell cycle arrest biomarkers win race for AKI diagnosis

FDA approval of the first device to use novel biomarkers of kidney damage to assess risk of acute kidney injury (AKI) potentially brings forward diagnosis of moderate-to-severe AKI to a time frame that could enable early intervention. Although the device awaits greater scrutiny, its approval marks the beginning of a new era.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. FDA news release. FDA allows marketing of the first test to assess risk of developing acute kidney injury [online], (2014).

  2. Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for acute kidney injury. Section 2: AKI Definition. Kidney Int. Suppl. 2, 7–24 (2012).

  3. Hoste, E. A. et al. Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol. Dial. Transpl. http://dx.doi.org/10.1093/ndt/gfu292.

  4. Bihorac, A. et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am. J. Respir. Crit. Care Med. 189, 932–939 (2014).

    Article  CAS  Google Scholar 

  5. Kashani, K. et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit. Care 17, R25 (2013).

    Article  Google Scholar 

  6. McCullough, P. A. et al. Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib. Nephrol. 182, 5–12 (2013).

    Article  Google Scholar 

  7. Nickolas, T. L. et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study. J. Am. Coll. Cardiol. 59, 246–255 (2012).

    Article  CAS  Google Scholar 

  8. Pickering, J. W. & Endre, Z. H. Linking injury to outcome in acute kidney injury: a matter of sensitivity. PLoS ONE 8, e62691 (2013).

    Article  CAS  Google Scholar 

  9. Endre, Z. H. et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int. 79, 1119–1130 (2011).

    Article  CAS  Google Scholar 

  10. Endre, Z. H. & Pickering, J. W. Biomarkers and creatinine in AKI: the trough of disillusionment or the slope of enlightenment? Kidney Int. 84, 644–647 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Zoltán H. Endre.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Endre, Z., Pickering, J. Cell cycle arrest biomarkers win race for AKI diagnosis. Nat Rev Nephrol 10, 683–685 (2014). https://doi.org/10.1038/nrneph.2014.198

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2014.198

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research